MARKET

GKOS

GKOS

Glaukos Corp
NYSE
138.80
+1.51
+1.10%
Opening 12:39 05/14 EDT
OPEN
137.78
PREV CLOSE
137.29
HIGH
139.99
LOW
136.34
VOLUME
132.79K
TURNOVER
--
52 WEEK HIGH
146.75
52 WEEK LOW
73.16
MARKET CAP
8.15B
P/E (TTM)
-42.1705
1D
5D
1M
3M
1Y
5Y
1D
Insider Move at Glaukos: Director’s Bold Stock Sale Turns Heads
TipRanks · 14h ago
Medical Device Stocks Are Ready to Bounce. Two Names to Buy Now.
Barron‘s · 21h ago
Weekly Report: what happened at GKOS last week (0504-0508)?
Weekly Report · 3d ago
Glaukos (GKOS) Is Up 15.7% After Raising 2026 Sales Guidance And Expanding Ophthalmic Portfolio – What's Changed
Simply Wall St · 6d ago
Top Glaukos Insiders Cash In With Major Stock Sell-Off
TipRanks · 05/05 02:03
A Look At Glaukos (GKOS) Valuation After Raised 2026 Sales Guidance And Strong First Quarter Revenue
Simply Wall St · 05/05 00:33
Weekly Report: what happened at GKOS last week (0427-0501)?
Weekly Report · 05/04 10:05
Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX) and Glaukos (GKOS)
TipRanks · 05/04 04:00
More
About GKOS
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.

Webull offers Glaukos Corp stock information, including NYSE: GKOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GKOS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GKOS stock methods without spending real money on the virtual paper trading platform.